Transcription factor decoy against stem cells master regulators, Nanog and Oct-4: a possible approach for differentiation therapy

Tumor Biology

Volumn 36, Issue 4, 2015, Pages 2621-2629

  Rad, Seyed Mohammad Ali Hosseini ^a,b,c,d,e,f   Bamdad, Taravat ^a,b,c,d,e,f   Sadeghizadeh, Majid ^a,b,c,d,e,f   Arefian, Ehsan ^a,b,c,d,e,f   Lotfinia, Majid ^a,b,c,d,e,f   Ghanipour, Milad ^a,b,c,d,e,f  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b STEM CELL TECHNOLOGY RESEARCH CENTER   (Iran)

^c UNIVERSITY OF TEHRAN   (Iran)

^d ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

^e PASTEUR INSTITUTE OF IRAN   (Iran)

^f BANGALORE UNIVERSITY   (India)

Author keywords

Cancer Stem Cells; Nanog; P19 cells; Stemness; Transcription factor decoy

Indexed keywords

HOMEODOMAIN PROTEIN; NANOG PROTEIN, HUMAN; OCTAMER TRANSCRIPTION FACTOR 4; OLIGONUCLEOTIDE; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

CANCER STEM CELL; CELL DIFFERENTIATION; EMBRYONIC STEM CELL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NEOPLASMS; PATHOLOGY; REGULATORY SEQUENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL LINE, TUMOR; EMBRYONIC STEM CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; OLIGONUCLEOTIDES; REGULATORY SEQUENCES, NUCLEIC ACID; SIGNAL TRANSDUCTION; SOXB1 TRANSCRIPTION FACTORS;

EID: 84936767110     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2884-y     Document Type: Article

References (74)

1. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007;8:173–84.
2. Dass CR, Choong PF. Targeting of small molecule anticancer drugs to the tumour and its vasculature using cationic liposomes: lessons from gene therapy. Cancer Cell Int. 2006;6:17.
3. Kumar R, Dammai V, Yadava PK, Kleinau S. Gene targeting by ribozyme against TNF-alpha mRNA inhibits autoimmune arthritis. Gene Ther. 2005;12:1486–93.
4. Wang DY, Lai BH, Sen D. A general strategy for effector-mediated control of RNA-cleaving ribozymes and DNA enzymes. J Mol Biol. 2002;318:33–43.
5. Bielinska A, Shivdasani RA, Zhang LQ, Nabel GJ. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science. 1990;250:997–1000.
6. Penolazzi L, Lambertini E, Aguiari G, del Senno L, Piva R. Modulation of estrogen receptor gene expression in human breast cancer cells: a decoy strategy with specific PCR-generated DNA fragments. Breast Cancer Res Treat. 1998;49:227–35.
7. Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res. 1998;82:1023–8.
8. Khaled AR, Butfiloski EJ, Sobel ES, Schiffenbauer J. Use of phosphorothioate-modified oligodeoxynucleotides to inhibit NF-kappaB expression and lymphocyte function. Clin Immunol Immunopathol. 1998;86:170–9.
9. Gao H, Xiao J, Sun Q, Lin H, Bai Y, Yang L, et al. A single decoy oligodeoxynucleotides targeting multiple oncoproteins produces strong anticancer effects. Mol Pharmacol. 2006;70:1621–9.
10. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakama M, Zhang L, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A. 1995;92:5855–9.
11. Ahn JD, Kim CH, Magae J, Kim YH, Kim HJ, Park KK, et al. E2F decoy oligodeoxynucleotides effectively inhibit growth of human tumor cells. Biochem Biophys Res Commun. 2003;310:1048–53.
12. Suzuki J, Isobe M, Morishita R, Izawa A, Yamazaki S, Okubo Y, et al. E2F decoy suppresses E-selectin expression in murine cardiac allograft arteriopathy. Transplant Proc. 1999;31:2018–9.
13. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A. 2003;100:4138–43.
14. Zhang X, Liu P, Zhang B, Wang A, Yang M. Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells. Cancer Genet Cytogenet. 2010;197:46–53.
15. Takahashi T, Togo S, Kumamoto T, Watanabe K, Kubota T, Ichikawa Y, et al. Transfection of NF-kappaB decoy oligodeoxynucleotides into macrophages reduces murine fatal liver failure after excessive hepatectomy. J Surg Res. 2009;154:179–86.
16. Ohmori K, Takeda S, Miyoshi S, Minami M, Nakane S, Ohta M, et al. Attenuation of lung injury in allograft rejection using NF-kappaB decoy transfection-novel strategy for use in lung transplantation. Eur J Cardiothorac Surg. 2005;27:23–7.
17. Kawamura I, Morishita R, Tsujimoto S, Manda T, Tomoi M, Tomita N, et al. Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. Gene Ther. 2001;8:905–12.
18. Chae YM, Park KK, Lee IK, Kim JK, Kim CH, Chang YC. Ring-Sp1 decoy oligonucleotide effectively suppresses extracellular matrix gene expression and fibrosis of rat kidney induced by unilateral ureteral obstruction. Gene Ther. 2006;13:430–9.
19. Park JH, Jo JH, Kim KH, Kim SJ, Lee WR, Park KK, et al. Antifibrotic effect through the regulation of transcription factor using ring type-Sp1 decoy oligodeoxynucleotide in carbon tetrachloride-induced liver fibrosis. J Gene Med. 2009;11:824–33.
20. Alper O, Bergmann-Leitner ES, Abrams S, Cho-Chung YS. Apoptosis, growth arrest and suppression of invasiveness by CRE-decoy oligonucleotide in ovarian cancer cells: protein kinase a downregulation and cytoplasmic export of CRE-binding proteins. Mol Cell Biochem. 2001;218:55–63.
21. Liu WM, Scott KA, Shahin S, Propper DJ. The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines. Eur J Biochem. 2004;271:2773–81.
22. Cho WH, Kim HT, Koo JH, Lee IK. Effect of AP-1 decoy using hemagglutinating virus of Japan-liposome on the intimal hyperplasia of the autogenous vein graft in mongrel dogs. Transplant Proc. 2006;38:2161–3.
23. Holschermann H, Stadlbauer TH, Wagner AH, Fingerhuth H, Muth H, Rong S, et al. STAT-1 and AP-1 decoy oligonucleotide therapy delays acute rejection and prolongs cardiac allograft survival. Cardiovasc Res. 2006;71:527–36.
24. Nishitsuji H, Tamura Y, Fuse T, Habu Y, Miyano-Kurosaki N, Takaku H. Inhibition of HIV-1 replication by 5'LTR decoy RNA. Nucleic Acids Res Suppl. 2001;1:141–2.
25. Li MJ, Kim J, Li S, Zaia J, Yee JK, Anderson J, et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCr5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther. 2005;12:900–9.
26. Zhang J, Yamada O, Sakamoto T, Yoshida H, Araki H, Murata T, et al. Inhibition of hepatitis C virus replication by pol III-directed overexpression of RNA decoys corresponding to stem-loop structures in the NS5B coding region. Virology. 2005;342:276–85.
27. Ward RJ, Dirks PB. Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol. 2007;2:175–89.
28. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.
29. Sell S. Leukemia: stem cells, maturation arrest, and differentiation therapy. Stem Cell Rev. 2005;1:197–205.
30. Ivanova N, Dobrin R, Lu R, Kotenko L, Levorse J, DeCoste C, et al. Dissecting self-renewal in stem cells with RNA interference. Nature. 2006;44:533–8.
31. Dejosez M, Krumenacker JS, Zitur LJ, Passeri M, Chu LF, Songyang Z, et al. Ronin is essential for embryogenesis and the pluripotency of mouse embryonic stem cells. Cell. 2008;133:1162–74.
32. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005;122:947–56.
33. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 2003;113:631–42.
34. Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet. 2006;38:431–40.
35. Chen X, Xu H, Yuan P, Fang F, Huss M, Vega VB, et al. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell. 2008;133:1106–17.
36. Chambers I, Tomlinson SR. The transcriptional foundation of pluripotency. Development. 2009;136:2311–22.
37. Wu Q, Chen X, Zhang J, Loh YH, Low TY, Zhang W, et al. Sall4 interacts with Nanog and co-occupies Nanog genomic sites in embryonic stem cells. J Biol Chem. 2006;281:24090–4.
38. Ishiguro T, Sato A, Ohata H, Sakai H, Nakagama H, Okamoto K. Differential expression of nanog1 and nanogp8 in colon cancer cells. Biochem Biophys Res Commun. 2011;418:199–204.
39. Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem. 2009;284:26533–46.
40. Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem. 2008;283:17635–51.
41. Zhang J, Wang X, Li M, Han J, Chen B, Wang B, et al. NANOGP8 is a retrogene expressed in cancers. FEBS J. 2006;273:1723–30.
42. Ambady S, Malcuit C, Kashpur O, Kole D, Holmes WF, Hedblom E, et al. Expression of NANOG and NANOGP8 in a variety of undifferentiated and differentiated human cells. Int J Dev Biol. 2010;54:1743–54.
43. Gehring WJ, Qian YQ, Billeter M, Furukubo-Tokunaga K, Schier AF, Resendez-Perez D, et al. Homeodomain-DNA recognition. Cell. 1994;78:211–23.
44. Jauch R, Ng CK, Saikatendu KS, Stevens RC, Kolatkar PR. Crystal structure and DNA binding of the homeodomain of the stem cell transcription factor Nanog. J Mol Biol. 2008;376:758–70.
45. Klemm JD, Rould MA, Aurora R, Herr W, Pabo CO. Crystal structure of the Oct-1 POU domain bound to an octamer site: DNA recognition with tethered DNA-binding modules. Cell. 1994;77:21–32.
46. Phillips K, Luisi B. The virtuoso of versatility: POU proteins that flex to fit. J Mol Biol. 2000;302:1023–39.
47. Yeom YI, Fuhrmann G, Ovitt CE, Brehm A, Ohbo K, Gross M, et al. Germline regulatory element of Oct-4 specific for the totipotent cycle of embryonal cells. Development. 1996;122:881–94.
48. Nordhoff V, Hubner K, Bauer A, Orlova I, Malapetsa A, Scholer HR. Comparative analysis of human, bovine, and murine Oct-4 upstream promoter sequences. Mamm Genome. 2001;12:309–17.
49. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev. 2003;17:126–40.
50. Bowles J, Schepers G, Koopman P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol. 2000;227:239–55.
51. Ambrosetti DC, Basilico C, Dailey L. Synergistic activation of the fibroblast growth factor 4 enhancer by Sox2 and Oct-3 depends on protein-protein interactions facilitated by a specific spatial arrangement of factor binding sites. Mol Cell Biol. 1997;17:6321–9.
52. Ambrosetti DC, Scholer HR, Dailey L, Basilico C. Modulation of the activity of multiple transcriptional activation domains by the DNA binding domains mediates the synergistic action of Sox2 and Oct-3 on the fibroblast growth factor-4 enhancer. J Biol Chem. 2000;275:23387–97.
53. Jiang J, Chan YS, Loh YH, Cai J, Tong GQ, Lim CA, et al. A core Klf circuitry regulates self-renewal of embryonic stem cells. Nat Cell Biol. 2008;10:353–60.
54. Nakatake Y, Fukui N, Iwamatsu Y, Masui S, Takahashi K, Yagi R, et al. Klf4 cooperates with Oct3/4 and Sox2 to activate the Lefty1 core promoter in embryonic stem cells. Mol Cell Biol. 2006;26:7772–82.
55. Chew JL, Loh YH, Zhang W, Chen X, Tam WL, Yeap LS, et al. Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol. 2005;25:6031–46.
56. Odom DT, Dowell RD, Jacobsen ES, Nekludova L, Rolfe PA, Danford TW, et al. Core transcriptional regulatory circuitry in human hepatocytes. Mol Syst Biol. 2006;2:2006.0017.
57. McBurney MW, Rogers BJ. Isolation of male embryonal carcinoma cells and their chromosome replication patterns. Dev Biol. 1982;89:503–8.
58. McBurney MW. P19 embryonal carcinoma cells. Int J Dev Biol. 1993;37:135–40.
59. Choi SC, Choi JH, Shim WJ, Lim DS. P19 embryonal carcinoma cells: a new model for the study of endothelial cell differentiation. Biotechnol Lett. 2008;30:1169–75.
60. Liour SS, Kapitonov D, Yu RK. Expression of gangliosides in neuronal development of p19 embryonal carcinoma stem cells. J Neurosci Res. 2000;62:363–73.
61. Gianakopoulos PJ, Skerjanc IS. Hedgehog signaling induces cardiomyogenesis in P19 cells. J Biol Chem. 2005;280:21022–8.
62. Bakhshalizadeh S, Esmaeili F, Houshmand F, Shirzad H, Saedi M. Effects of selegiline, a monoamine oxidase B inhibitor, on differentiation of P19 embryonal carcinoma stem cells, into neuron-like cells. In Vitro Cell Dev Biol Anim. 2011;47:550–7.
63. Xu XS, Hong X, Wang G. Induction of endogenous gamma-globin gene expression with decoy oligonucleotide targeting Oct-1 transcription factor consensus sequence. J Hematol Oncol. 2009;2:15.
64. Niwa H, Ogawa K, Shimosato D, Adachi K. A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. Nature. 2009;460:118–22.
65. Yang J, Gao C, Chai L, Ma Y. A novel SALL4/OCT4 transcriptional feedback network for pluripotency of embryonic stem cells. PLoS One. 2010;5:e10766.
66. Zhang J, Tam WL, Tong GQ, Wu Q, Chan HY, Soh BS, et al. Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1. Nat Cell Biol. 2006;8:1114–23.
67. Omidi Y, Barar J, Heidari HR, Ahmadian S, Yazdi HA, Akhtar S. Microarray analysis of the toxicogenomics and the genotoxic potential of a cationic lipid-based gene delivery nanosystem in human alveolar epithelial a549 cells. Toxicol Mech Methods. 2008;18:369–78.
68. Shan J, Shen J, Liu L, Xia F, Xu C, Duan G, et al. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology. 2012;56:1004–14.
69. Chen WJ, Ho CC, Chang YL, Chen HY, Lin CA, Ling TY, et al. Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat Commun. 2014;5:3472.
70. Pramfalk C, Lanner J, Andersson M, Danielsson E, Kaiser C, Renstrom IM, et al. Insulin receptor activation and down-regulation by cationic lipid transfection reagents. BMC Cell Biol. 2004;5:7.
71. Mann MJ, Dzau VJ. Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest. 2000;106:1071–5.
72. Lu R, Yang A, Jin Y. Dual functions of T-box 3 (Tbx3) in the control of self-renewal and extraembryonic endoderm differentiation in mouse embryonic stem cells. J Biol chem. 2011;286:8425–36.
73. Hough SR, Clements I, Welch PJ, Wiederholt KA. Differentiation of mouse embryonic stem cells after RNA interference-mediated silencing of OCT4 and Nanog. Stem Cells. 2006;24:1467–75.
74. Hu G, Kim J, Xu Q, Leng Y, Orkin SH, Elledge SJ. A genome-wide RNAi screen identifies a new transcriptional module required for self-renewal. Genes Dev. 2009;23:837–48.